Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 47, Issue 6, 2008, Pages 700-708

  Wilens, Timothy E ^a   Boellner, Samuel W ^b   López, Frank A ^c   Turnbow, John M ^d   Wigal, Sharon B ^e   Childress, Ann C ^f   Abikoff, Howard B ^g   Manos, Michael J ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Neurology and Clinical Study Centers   (United States)

^c Children's Developmental Center

^d Westex Clinical Investigations ^*

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Center for Psychiatry and Behavioral Medicine Inc   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Methylphenidate transdermal system; Stimulants

Indexed keywords

METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; APPLICATION SITE DISCOMFORT; APPLICATION SITE ERYTHEMA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERMANENT PRODUCT MEASURE OF PERFORMANCE MATH TEST; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SWANSON KOTKIN AGLER MFLYNN AND PELHAM RATING SCALE; TRANSDERMAL PATCH; TREATMENT DURATION; ADOLESCENT; ATTENTION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; INTRADERMAL DRUG ADMINISTRATION; PERSONALITY TEST; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PERSONALITY ASSESSMENT; TREATMENT OUTCOME;

EID: 44849099627     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/CHI.0b013e31816bffdf     Document Type: Article

References (26)

1. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
2. American Academy of Pediatrics Diagnostic Guidelines. Statements of clinical relevance. Pediatrics. 2000;105:1158-1170.
3. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104-113.
4. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546-557.
5. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792-1798.
6. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524-540.
7. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up: V. Replication of psychiatric status. Arch Gen Psychiatry. 1991;48:77-83.
8. Patrick KS, Caldwell RW, Ferris RM, et al. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther. 1987;241:152-158.
9. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180-187.
10. Wilens TE, Spencer TJ . The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9:573-603.
11. Robison LM, Sclar DA, Skaer TL, et al. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr (Phila). 1999;38:209-217.
12. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attemion-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 2003;23:1281-1299.
13. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-211.
14. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;40:1352-1355.
15. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord. 2006;9:476-485.
16. Heal DJ, Pierce DM . Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 2006;20:713-738.
17. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol. 2005;13:111-126.
18. Pelham WE Jr, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:522-529.
19. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10:92-111.
20. Collett BR, Ohan JL, Myers KM. Ten-year review of racing scales: V. Scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003;42:1015-1037.
21. Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34:47-53.
22. Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperactiviry disorder in children. Drugs. 2006;66:1117-1126.
23. Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactiviry disorder in children. Clin Pharmacol Ther. 1999;66:295-305.
24. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs. 2003;5:833-841.
25. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112:e404.
26. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892.